Other equities research analysts have also recently issued research reports about the company. Deutsche Bank reiterated a buy rating and issued a GBX 775 ($10.43) price objective on shares of BTG in a research note on Tuesday, November 7th. Stifel Nicolaus reiterated a buy rating and issued a GBX 800 ($10.77) price objective on shares of BTG in a research note on Wednesday, August 30th. Peel Hunt reiterated a hold rating and issued a GBX 680 ($9.15) price objective on shares of BTG in a research note on Wednesday, September 20th. Finally, J P Morgan Chase & Co reiterated a neutral rating on shares of BTG in a research note on Wednesday, November 15th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. BTG has an average rating of Buy and a consensus target price of GBX 771.63 ($10.39).
BTG (LON:BTG) traded up GBX 16.98 ($0.23) during mid-day trading on Friday, reaching GBX 731 ($9.84). The company had a trading volume of 507,934 shares, compared to its average volume of 726,872. BTG has a 12-month low of GBX 528.36 ($7.11) and a 12-month high of GBX 779 ($10.48).
BTG (LON:BTG) last issued its quarterly earnings data on Tuesday, November 14th. The company reported GBX 21 ($0.28) earnings per share for the quarter, meeting the Zacks’ consensus estimate of GBX 21 ($0.28). BTG had a return on equity of 10.80% and a net margin of 15.50%. The company had revenue of £341.30 million during the quarter.
ILLEGAL ACTIVITY WARNING: “BTG’s (BTG) “Buy” Rating Reaffirmed at Numis Securities” was originally published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://transcriptdaily.com/2017/12/09/btgs-btg-buy-rating-reaffirmed-at-numis-securities.html.
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with MarketBeat.com's FREE daily email newsletter.